Ipilimumab has activity in some patients with advanced melanoma and brain metastases — particularly when metastases are small and asymptomatic — with no unexpected toxic effects, investigators concluded in the Lancet Oncology online March 26.
Three patients with BRAF-positive stage IV melanoma who had cutaneous toxic effects following vemurafenib administration—including sequela not previously reported—suggests BRAF inhibition alone may be sufficient to induce such changes, a study published in Archives of Dermatology online March 19 has found.
Outlook for patients with thin melanomas is positive say the authors of a study recently published in the Journal of Clinical Oncology.
Patients with advanced stage melanoma may have promising combination therapy.
Alternative clinical strategies have the potential to overcome the underlying acquired B-RAF inhibitor resistance that can hamper long-term therapeutic success in melanoma.
Sunitinib, a tyrosine kinase inhibitor, has been approved by the FDA for the treatment of kidney cancer and stromal gastrointestinal cancer, but its effectiveness in melanoma was unknown until this study.
Several factors, including sporting activity, physical workload, and smoking habits, affect the sonomorphologic characteristics of peripheral lymph nodes (LNs) in patients with a history of invasive cutaneous melanoma.
Experts tell Chemotherapy Advisor that new consumer-targeted cancer-screening apps may put patients at risk.
A minimal, less-toxic conditioning treatment with cyclophosphamide, which allows cytotoxic T-lymphocyte clones to survive for longer, shows some clinical benefit in patients with refractory, metastatic melanoma.
Melanoma patients may have received a shot of life today with news that a vaccine for the deadly cancer has received FDA clearance for Phase 3 clinical testing.
